Nanobiotix S.A. (FRA:5NR)

Market Cap	1.06B +454.8%
Revenue (ttm)	10.16M -75.9%
Net Income	-51.64M
EPS	-1.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45
Average Volume	137
Open	22.00
Previous Close	21.65
Day's Range	22.00 - 24.35
52-Week Range	2.53 - 27.70
Beta	n/a
RSI	76.23
Earnings Date	Mar 17, 2026

About Nanobiotix

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBT...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 103
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5NR